本公告乃藥師幫股份有限公司（「本公司」）自 願 刊 發，以 告 知 其 股 東 及 潛 在 投 資 者有關本公司連同其附屬公司及綜合聯屬實體（「本集團」）若干業務發展最新 情 況。除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 本 公 司 於2025年4月25日刊發的年度 報 告（「年 報」）所 界 定 者 具 相 同 涵 義。 茲提述本公司日期為2025年5月14日 有 關 業 務 發 展 最 新 情 況 的 自 願 性 公 告。廠 牌首推業務乃本集團「向 上 走」方 案 中 的 一 項 重 要 戰 略，同 時 作 為 高 利 潤 業 務， 因 此 對 提 升 盈 利 能 力 而 言 舉 足 輕 重。誠 如 年 報 所 披 露，根 據 本 公 司 自 其 他 業 務 運 營 所 獲 得 的 洞 察，本 公 司 積 極 尋 求 與 藥 企 建 立 深 度 合 作，旨 在 協 助 它 們 將 針 對 下 游 需 求 定 制 的 產 品 推 向 更 廣 闊 的 市 場，從 而 將 潛 在 的 市 場 機 遇 轉 化 為 實 實 在 在 的 銷 售 業 績。另 一 方 面，依 託 本 公 司 已 經 構 ...

Group 1 - The core viewpoint is that Yaoshi Bang (09885) has shown strong market performance, with its stock price rising to 12.4 HKD, marking a year-to-date increase of over 142% since September 25 [1] - The continuous rise in stock price is attributed to the gradual alleviation of early investor selling pressure, optimization of the company's equity structure, and strong performance fundamentals [1] - The exit of early financial investors has created space for long-term institutional investors, enhancing the stability and quality of the shareholder base [1] Group 2 - In the first half of 2025, the company achieved a revenue of 9.843 billion CNY, a year-on-year increase of 11.7%, and a net profit of 78.117 million CNY, a surge of 258% compared to the same period in 2024 [2] - The change in equity structure is seen as a positive factor, allowing the market to focus more on the company's long-term narrative [2] - The valuation of the company remains attractive relative to its growth potential and industry position, with significant room for value re-evaluation if high growth expectations are met [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | 本 ...

Group 1: Hong Kong Stocks - China Metallurgical Group (01618) rose nearly 7%, with institutions stating that the value of this resource-rich construction company needs urgent reassessment [1] - Rongchang Bio (09995) increased over 5%, as its innovative ophthalmic drug RC28 has been submitted for listing, following a partnership with Santen China [1] - Laikang Pharmaceutical-B (02105) surged nearly 6%, with a cumulative increase of 36% over the last three trading days, driven by positive preliminary results from the Phase I clinical MAD study of LAE102 [1] - UBTECH Robotics (09880) rose over 5%, with a report from CMB International recommending UBTECH as the top pick in the humanoid robot sector and raising its target price [1] - Innovent Biologics (09969) increased over 6%, as the company announced the first prescriptions for Tanshitumomab in several provinces [1] - BrainCo-B (06681) surged over 16%, benefiting from policy catalysts in the brain-computer interface industry, with its cognitive impairment digital therapy product having a first-mover advantage [1] - Yaoshi Bang (09885) rose over 10%, with high-margin business accelerating growth and POCT devices expected to see increased deployment in the second half of the year [1] - DCH Holdings (00179) fell over 7%, as Citigroup downgraded its investment rating from "Buy" to "Neutral," citing limited upside potential for the stock [1] - Minmetals Resources (01208) rose over 2%, planning to issue $500 million zero-coupon convertible bonds maturing in 2030 for overseas debt refinancing [1][2] Group 2: US Stocks - Alibaba (BABA.US) rose 4.65%, with Morgan Stanley reiterating an "Overweight" rating and raising the ADR target price from $165 to $200 [3] - Li Auto (LI.US) increased 3.57%, as the Li One officially commenced delivery at the Changzhou smart manufacturing base, with a report indicating that the i6 model's sales performance is expected to outperform the i8 [3] - JD.com (JD.US) rose 0.15%, announcing that the 2025 Double 11 shopping festival will start on October 9 at 8 PM, two days earlier than last year [3] - Xpeng Motors (XPEV.US) increased 1.76%, with the company announcing that the Xpeng MONA M03 has delivered a total of 180,000 units [3] - New Oriental (EDU.US) rose 4.38%, with a report indicating that the overall business development of the group is stabilizing [3] - Merus (MRUS.US) surged 35.97%, following an agreement with Danish biotech company Genmab for a cash acquisition at $97 per share [3] - Novo Nordisk (NVO.US) fell 0.20%, as Morgan Stanley downgraded its rating to "Sell" and reduced the target price from $99 to $47 [4] - MoonLake (MLTX.US) plummeted 89.93%, with trial results for its therapeutic drug falling far below expectations, leading to a significant target price cut by RBC [4] - TSMC (TSM.US) fell 0.05%, reaffirming that it has not engaged in discussions regarding potential investments or collaborations with any companies [4] - Micron Technology (MU.US) rose 4.22%, with Morgan Stanley predicting that the storage industry price increase cycle may continue into next year [4]

Core Viewpoint - Yaoshi Bang (9885.HK) experienced a significant intraday surge of nearly 17%, reaching a three-month high of HKD 11.28, with a year-to-date increase exceeding 100% [1] Financial Performance - For the first half of 2025, Yaoshi Bang reported revenue of CNY 9.843 billion, representing a year-on-year growth of 11.7% [1] - The net profit attributable to shareholders exceeded CNY 78.117 million, marking a substantial year-on-year increase of 258%, continuing the high growth trend since returning to profitability in 2024 [1] - The company's gross margin improved to 11.2% year-on-year, driven by the high-margin characteristics of its proprietary brands [1] Market Outlook - Multiple investment banks have expressed optimism about Yaoshi Bang following the earnings announcement [1] - Cinda Securities' report indicates that Yaoshi Bang has transitioned from a capital investment phase to a performance harvesting phase, with an expected compound annual growth rate (CAGR) of 164% for net profit attributable to shareholders from 2024 to 2027 [1] - The company's "platform + service + ecosystem" business model is considered rare compared to peers, with a target valuation range of HKD 7.4 billion to HKD 13.4 billion, maintaining a "buy" rating [1] - CITIC Securities initiated coverage on Yaoshi Bang with a "buy" rating, anticipating continued improvement in profitability and accelerated development of diversified businesses in the second half of the year [1] Technological Advancements - The company is actively advancing the application of AI and robotics technology, focusing on empowering downstream customers and optimizing supply chain efficiency, which is expected to lead to collaborative growth in the future [1]

每经AI快讯，9月30日，港股药师帮(09885.HK)盘中涨超9%，截至发稿，涨9.12%，报10.55港元，成交 额3.2亿港元。 ...

Core Viewpoint - The stock of Yaoshi Bang (09885) has seen a significant increase of over 9%, currently trading at 10.55 HKD with a transaction volume of 320 million HKD, driven by positive research from CITIC Securities [1] Group 1: Business Performance - Yaoshi Bang launched its brand-first business in 2020, targeting high-demand product categories and partnering with upstream manufacturers to supply to grassroots medical institutions and pharmacies, achieving an excess gross margin [1] - The GMV of the brand-first business grew by 115.6% year-on-year to 1.08 billion CNY in the first half of 2025, with the self-owned brand GMV increasing by 473.4% year-on-year to 852 million CNY [1] - CITIC Securities believes that the company will continue to steadily increase the proportion of high-margin business, especially after acquiring a pharmaceutical segment that enriches its self-owned product matrix, potentially leading to additional growth [1] Group 2: Product Development and Market Expansion - In 2024, the company plans to launch three "Future Spectrum" series POCT devices, focusing on the grassroots medical institution market to enhance its basic disease detection capabilities [1] - As of June 30, 2025, the company has covered over 18,000 terminal institutions and deployed more than 23,000 units, with plans for accelerated deployment in the second half of 2025 [1] - The POCT devices will be integrated with the clinic's digital management system ("Spectrum Cloud Diagnosis" SaaS system) and AI-assisted systems (Spectrum Smart Doctor), aiming to improve clinic operations and user engagement [1] - The company is actively advancing the application of AI and robotics technology to enhance downstream customer empowerment and supply chain efficiency, which is expected to drive further growth [1]

Core Viewpoint - The stock of Yaoshi Bang (09885) has seen a significant increase of over 9%, driven by strong growth in its proprietary brand business and the introduction of new medical devices aimed at grassroots healthcare institutions [1][2] Group 1: Financial Performance - Yaoshi Bang's proprietary brand business GMV grew by 115.6% year-on-year to 1.08 billion yuan in the first half of 2025, with the higher-margin self-owned brand GMV increasing by 473.4% to 852 million yuan [1] - The company has achieved a trading volume of 320 million Hong Kong dollars, reflecting strong market interest [1] Group 2: Product Development and Market Strategy - In 2024, the company plans to launch three new "Future Spectrum" series POCT devices, focusing on the grassroots healthcare market to enhance its disease detection capabilities [2] - As of June 2025, the company has covered over 18,000 terminal institutions and deployed more than 23,000 units of its POCT devices, with plans for accelerated deployment in the second half of 2025 [2] - The POCT devices will be integrated with the "Spectrum Cloud Diagnosis" SaaS system and AI-assisted systems, aiming to improve clinic management and user engagement [2] Group 3: Future Growth Potential - The company is actively advancing the application of AI and robotics technology to enhance downstream customer capabilities and optimize supply chain efficiency, which is expected to drive further growth [2]

Core Viewpoint - Tianfeng Securities maintains a "buy" rating for Yaoshi Bang (09885) and raises the forecast for net profit attributable to shareholders for 2025-2027 from 1.56/3.73/6.02 billion to 1.79/4.03/6.50 billion, driven by strong performance in platform and self-operated businesses, as well as breakthroughs in proprietary brand business [1] Group 1: Platform Business - In H1 2025, the company's platform business generated revenue of 4.36 billion, reflecting a year-on-year increase of 11.66% [1] - The company enhanced the richness of its platform business products, increasing the average monthly SKU count to approximately 4 million, significantly meeting diverse user needs [1] - The company focused on the core value extraction of traditional Chinese medicine pieces, providing 125,000 SKUs to downstream customers, a year-on-year increase of 22.5% [1] Group 2: Self-Operated Business - In H1 2025, the self-operated business achieved revenue of 93.89 billion, a year-on-year increase of 12.5% [2] - The self-operated business provided an average monthly SKU count of 480,000, an increase of 58,000 SKUs in H1 2025 [2] - The proportion of same-city orders delivered within half a day increased to 70%, while the return rate decreased to 0.4% [2] - The company strengthened the direct supply model from manufacturers, optimizing procurement channels to reduce operational costs [2] Group 3: Proprietary Brand Business - In H1 2025, the transaction scale of the proprietary brand business reached 1.08 billion, a year-on-year increase of 115.6% [3] - The proprietary brand business contributed significantly to the high-quality growth of the self-operated business, with a transaction scale of 852 million, a year-on-year increase of approximately 473.4% [3] - The major product, Le Yaoshi Huoxiang Zhengqi Oral Liquid, achieved substantial breakthroughs in coverage at grassroots medical terminals [3]

Core Viewpoint - Tianfeng Securities maintains a "buy" rating for Yaoshi Bang (09885) and raises the forecast for net profit attributable to shareholders for 2025-2027 from 1.56/3.73/6.02 billion to 1.79/4.03/6.50 billion [1] Group 1: Platform Business - In H1 2025, the company's platform business generated revenue of 436 million, reflecting a year-on-year increase of 11.66% [1] - The company has enhanced the product richness of its platform business, increasing the average monthly SKU count to approximately 4 million, significantly meeting diverse user needs [1] - The company focused on the core value extraction of traditional Chinese medicine pieces, providing 125,000 SKUs to downstream buyers, a year-on-year increase of 22.5% [1] Group 2: Self-operated Business - In H1 2025, the self-operated business achieved revenue of 9.389 billion, a year-on-year increase of 12.5% [2] - The self-operated business provided an average monthly SKU count of 480,000, an increase of 58,000 SKUs [2] - The proportion of same-city orders delivered within half a day increased to 70%, and the return rate decreased to 0.4% [2] - The company strengthened its direct supply model and optimized procurement channels to reduce operational costs [2] Group 3: Proprietary Brand Business - In H1 2025, the transaction scale of the proprietary brand business reached 1.08 billion, a year-on-year increase of 115.6% [3] - The proprietary brand contributed significantly to the high-quality growth of the self-operated business, with a transaction scale of 852 million, a year-on-year increase of approximately 473.4% [3] - The major product, Le Yaoshi Huoxiang Zhengqi Oral Liquid, achieved substantial breakthroughs in coverage at grassroots medical terminals [3]